SK Bioscience Readies $1.3bn IPO Amid Rosy Vaccine Outlook
Expects Continued Rise In COVID-19 Vaccine Demand
Executive Summary
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
You may also be interested in...
Next Big Step: SK Bioscience Gears Up For Endemic COVID, Next Pandemic
With its COVID-19 vaccine development project nearing the finish line, SK Bioscience unveils an ambitious growth strategy which includes mergers and acquisitions and diversification into the cell and gene therapy sector.
Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021
Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.
Large-Scale Funding Rises In Korea Amid Biotech Investment Boom
After record venture capital activity around South Korean biotechs last year, the strong investment interest has persisted so far this year, with an increased number of companies receiving large-scale funding as the promising sector emerges amid the pandemic.